Clinical trials recruiting for Metastatic Colorectal Cancer

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
  NCT04689347 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
  NCT04547166 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 5 locations
• A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
  NCT07079631 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
  NCT05639413 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 45 locations
• A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
  NCT07543744 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
  NCT07255664 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
  NCT06412198 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
  NCT06493760 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
  NCT04929223 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 84 locations
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 164 locations
• A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
  NCT06792695 · Phase: Phase 2 · Ages: 18 Years to 130 Years · Sex: All (male and female) · 76 locations
• A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
  NCT07549412 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.
  NCT07263178 · Phase: Not specified · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
  NCT06749015 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer
  NCT05093907 · Phase: Phase 1, Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
  NCT06820463 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 65 locations
• A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
  NCT07416552 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
  NCT06551207 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
  NCT06218810 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy
  NCT05962502 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
  NCT06118762 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Combination Therapy for BRAF-V600E Metastatic CRCm
  NCT06411600 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
  NCT06824064 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
  NCT06202183 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 50 Years · Sex: All (male and female) · 1 location
• FAPI Molecular Imaging for Diagnosis of the CMS4 Unfavorable Colorectal Cancer Subtype
  NCT06191120 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer
  NCT06980532 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
  NCT06321081 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
  NCT01174121 · Phase: Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 1 location
• Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer
  NCT07718490 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Impact of Using the Oncogramme® Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer
  NCT05299840 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
  NCT06202001 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• JS212 Combination Therapies in Metastatic Colorectal Cancer
  NCT07503756 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer
  NCT05462236 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
  NCT07277322 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer
  NCT07559760 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• On-treatment Biomarkers in Metastatic Colorectal Cancer for Life
  NCT05755672 · Phase: Not specified · Ages: 18 Years to 110 Years · Sex: All (male and female) · 2 locations
• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
  NCT06625775 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 88 locations
• Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
  NCT05985954 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
  NCT06149481 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
  NCT06959550 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients
  NCT07314294 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
  NCT06341296 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer
  NCT07617610 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie
  NCT06808685 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
  NCT05462613 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers
  NCT06425133 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Sacituzumab Govitecan in Metastatic Colorectal Cancer
  NCT06243393 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
  NCT06245356 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Second-line Treatment of Metastatic Colorectal Cancer
  NCT06242067 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer
  NCT06776757 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis
  NCT06225843 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
  NCT06252649 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 291 locations
• Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
  NCT05725200 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Sulfasalazine in Patients With Metastatic Colorectal Cancer
  NCT06134388 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• TARGETed Therapy Drug MONITOring in DIGestive Oncology
  NCT05443087 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 29 locations
• Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)
  NCT06907342 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Impact of Radiotherapy on Oligometastatic Cancer
  NCT05933876 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
  NCT06867822 · Phase: Phase 1 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
  NCT05007132 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases
  NCT05787197 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 16 locations

Related conditions

Trials recruiting for Metastatic Colorectal Cancer often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Metastatic Colorectal Cancer trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.